The former president of AstraZeneca UK and the ABPI has given up big pharma to join biotech Redx. We speak to her about what prompted the change, how she thinks British life science will fare in the coming years, and how the UK can help smaller companies like Redx to thrive
There are only two weeks to go until the 31 October deadline, don't miss it - get your entry in now!Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals.
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
At just 20 years old Kirsty Mills received a shock diagnosis of liver cirrhosis, following diagnoses of autoimmune hepatitis and lupus. She talks about her experiences with these conditions, and is keen to challenge the misconception that liver disease is all too often associated only with drug and alcohol abuse